CQ

CQ is a potent inhibitor of alpha-glucosidase

Chloroquine is a Toll-like receptor inhibitor that inhibits autophagy. Chloroquine has anti-malarial and anti-inflammatory activity and is widely used in the treatment of malaria and rheumatoid arthritis. Chloroquine also has anti-SARS-CoV-2 (COVID-19) activity and anti-HIV-1 activity.

CQ-ER is a Coumarin-quinazolinone-based photosensitizer targeting the endoplasmic reticulum (ER). It induces ferroptosis, thereby enhancing photodynamic therapy (PDT).

CQ-Mito, a derivative of CQ, demonstrates excellent phototherapeutic efficacy with a PI value of 167. This compound induces cell death through mechanisms such as apoptosis and ferroptosis. It mediates mitochondrial dysfunction, characterized by alterations in mitochondrial morphology and loss of MMP. Additionally, CQ-Mito effectively inhibits tumor growth in 3D multicellular tumor spheroid models.

CQ-16 is an orally active small molecule drug conjugate (SMDC) that targets prostate-specific membrane antigen (PSMA). It exhibits high selectivity in its antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. Additionally, CQ-16 possesses PARP inhibitory activity (IC50=1 nM).

Werner syndrome RecQ helicase-IN-1 is a potent Werne r syndrome RecQ DNA deconjugase (WRN) inhibitor that can be used to study cancers such as colon and stomach cancer.

CQ211 is a potent and selective RIOK2 inhibitor with a Kd of 6.1 nM, demonstrating significant proliferation inhibitory activity against various cancer cell lines in vitro.

Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.

NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).

MBCQ is an inhibitor of cGMP-specific phosphodiesterase PDE5.

CQ80 is an inhibitor of PEPD XPNPEP1, functioning by activating the CARD8 inflammasome.

Jacquinelin is a useful organic compound for research related to life sciences. The catalog number is T124235 and the CAS number is 7726-34-3.

(±)-CBCQ, an oxidation product of cannabidiol, exhibits an EC50 value of 14.7 μM for the activation of peroxisome proliferator-activated receptor γ (PPAR-γ).

CQ627 is a molecular glue that targets the degradation of RIOK2. It effectively recruits the E3 ubiquitin ligase RNF126, inducing the proteasomal degradation of RIOK2 via the ubiquitin-proteasome system (UPS) in MOLT4 leukemia cell lines, with a DC50 value of 410 nM. Additionally, CQ627 induces apoptosis in a dose-dependent manner in these cells, blocking the cell cycle at the G2 M phase, and exhibits antiproliferative activity across various cancer cell lines. It also demonstrates in vivo anticancer activity in MOLT4 xenograft mouse models.

CQ1373 is a potent RET inhibitor that demonstrates cellular activity against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C, and CCDC6-RET-G810R, with IC50 values of 13.0, 25.7, and 28.4 nM, respectively. It shows excellent selectivity for wild-type RET and solvent front mutants G810C R, with IC50 values of 4.2, 7.1, and 32.4 nM. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. Additionally, it induces apoptosis (Apoptosis) and cell cycle arrest in BaF3 cells. CQ1373 possesses antitumor efficacy, making it a candidate for cancer research.

DCQVA is a biochemical.

NLCQ-1 is a novel weak DNA-intercalative bioreductive compound. NLCQ-1 exhibited a C50 of 44 microM. NLCQ-1 demonstrated significant hypoxic selectivity in several rodent (V79, EMT6, SCCVII) or human (A549, OVCAR-3) tumor cell lines. Its potency as a hypo

RECQL5-IN-1 is an orally active inhibitor of RECQL5 (targeting both enzymatic and non-enzymatic domains) and is a potent inhibitor of RECQL5 decapping activity (IC50 46.3 nM): RECQL5-IN-1 can be used to study breast cancer.

NCQ-469 is a metabolite of remoxipride and a dopamine D2 receptor antagonist.

Werner syndrome RecQ helicase-IN-2 is an effective inhibitor of Werner syndrome RecQ DNA helicase (WRN), used in studying colorectal and gastric cancer.

Werner syndrome RecQ helicase-IN-3, a potent and orally active inhibitor of Werner syndrome RecQ helicase (WRN), exhibits anticancer and antiproliferative activities with an IC50 value of 0.06 µM.

Werner syndrome RecQ helicase-IN-4 is an effective inhibitor of Werner syndrome RecQ DNA helicase (WRN), exhibiting anticancer and antiproliferative activities, used for colorectal and gastric cancer research.

Succinamic acid acts as a weak inhibitor of human LL-xylose reductase (human LL-xylose reductase) with an IC50 of 1.45 mM. It is also utilized as a linker in the synthesis of CQ-16.

JMI-105 has the potential as an antimalarial agent. JMI-105 is a potent inhibitor of Plasmodium falciparum falcipain-2 protease (PfFP-2) that inhibits the P. falciparum strains CQ S (3D7) and CQ R (RKL-9) growth with IC 50 values of 8.8 μM and 14.3 μM. In a murine model with P. berghei ANKA infection, JMI-105 significantly decreases parasitemia and prolonged host survival [1].